$2.84
2.07% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US68619K2042
Symbol
ORGS
Sector
Industry

Orgenesis Inc. Stock price

$2.84
+1.63 134.71% 1M
-3.50 55.21% 6M
-2.17 43.28% YTD
-1.96 40.83% 1Y
-25.96 90.14% 3Y
-34.66 92.43% 5Y
-53.56 94.96% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.06 2.07%
ISIN
US68619K2042
Symbol
ORGS
Sector
Industry

Key metrics

Market capitalization $14.68m
Enterprise Value $30.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 34.26
P/S ratio (TTM) P/S ratio 16.31
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -93.57%
Revenue (TTM) Revenue $900.00k
EBIT (operating result TTM) EBIT $-25.87m
Free Cash Flow (TTM) Free Cash Flow $-15.74m
Cash position $1.12m
EPS (TTM) EPS $-9.26
Short interest 1.33%
Show more

Is Orgenesis Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Orgenesis Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Orgenesis Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Orgenesis Inc.:

Buy
100%

Financial data from Orgenesis Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.90 0.90
94% 94%
100%
- Direct Costs 3.08 3.08
59% 59%
342%
-2.18 -2.18
134% 134%
-242%
- Selling and Administrative Expenses 11 11
73% 73%
1,219%
- Research and Development Expense 11 11
17% 17%
1,211%
-24 -24
49% 49%
-2,672%
- Depreciation and Amortization 1.82 1.82
3% 3%
202%
EBIT (Operating Income) EBIT -26 -26
47% 47%
-2,875%
Net Profit -34 -34
39% 39%
-3,823%

In millions USD.

Don't miss a Thing! We will send you all news about Orgenesis Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Orgenesis Inc. Stock News

Neutral
GlobeNewsWire
4 months ago
Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete  response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a real-world study
Neutral
GlobeNewsWire
5 months ago
The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed j...

Company Profile

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment through MaSTherCell, comprises of services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution. The POC segment provides multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Head office United States
CEO Vered Caplan
Employees 146
Founded 2008
Website www.orgenesis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today